Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Eur Urol. 2023 Mar 8;84(3):275–286. doi: 10.1016/j.eururo.2023.02.016

Table 3 –

Adverse event data

Adverse event a Acute b Late c Overall

Nausea 3 0 3
Vomiting 2 0 2
Creatinine increase 0 2 2
Urinary frequency 1 0 1
Thrombocytopenia 0 1 1
Hematuria 1 0 1
Fatigue 0 1 1
Total 7 4 11
a

All events were grade 1.

b

Present in the first 3 mo of follow-up.

c

Present at longer than 3-mo follow-up.